Mendus Past Earnings Performance
Past criteria checks 0/6
Mendus's earnings have been declining at an average annual rate of -11.5%, while the Biotechs industry saw earnings declining at 1.4% annually. Revenues have been growing at an average rate of 5% per year.
Key information
-11.5%
Earnings growth rate
23.3%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 5.0% |
| Return on equity | -14.4% |
| Net Margin | -356.7% |
| Next Earnings Update | 17 May 2024 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20
Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Revenue & Expenses BreakdownBeta
How Mendus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 28 | -102 | 37 | 93 |
| 30 Sep 23 | 1 | -104 | 41 | 84 |
| 30 Jun 23 | 1 | -116 | 49 | 89 |
| 31 Mar 23 | 1 | -141 | 50 | 88 |
| 31 Dec 22 | 3 | -139 | 49 | 87 |
| 30 Sep 22 | 2 | -128 | 47 | 79 |
| 30 Jun 22 | 2 | -117 | 41 | 72 |
| 31 Mar 22 | 2 | -119 | 41 | 75 |
| 31 Dec 21 | 0 | -133 | 43 | 86 |
| 30 Sep 21 | 0 | -148 | 41 | 83 |
| 30 Jun 21 | 0 | -138 | 34 | 80 |
| 31 Mar 21 | 0 | -119 | 27 | 68 |
| 31 Dec 20 | 0 | -89 | 18 | 48 |
| 30 Sep 20 | 16 | 3 | 2 | 7 |
| 30 Jun 20 | 16 | -11 | 4 | 19 |
| 31 Mar 20 | 17 | -31 | 9 | 35 |
| 31 Dec 19 | 17 | -48 | 13 | 49 |
| 30 Sep 19 | 0 | -118 | 26 | 91 |
| 30 Jun 19 | 0 | -112 | 27 | 85 |
| 31 Mar 19 | 0 | -98 | 26 | 72 |
| 31 Dec 18 | 0 | -98 | 26 | 71 |
| 30 Sep 18 | 0 | -90 | 25 | 66 |
| 30 Jun 18 | 0 | -89 | 23 | 65 |
| 31 Mar 18 | 0 | -88 | 22 | 66 |
| 31 Dec 17 | 0 | -80 | 23 | 58 |
| 30 Sep 17 | 0 | -86 | 41 | 45 |
| 30 Jun 17 | 0 | -77 | 48 | 28 |
| 31 Mar 17 | 0 | -72 | 58 | 14 |
| 31 Dec 16 | 0 | -61 | 61 | 0 |
| 30 Sep 16 | 0 | -48 | 47 | 0 |
| 30 Jun 16 | 0 | -44 | 43 | 0 |
| 31 Mar 16 | 0 | -37 | 37 | 0 |
| 31 Dec 15 | 0 | -38 | 38 | 0 |
| 30 Sep 15 | 0 | -37 | 38 | 0 |
| 30 Jun 15 | 0 | -36 | 36 | 0 |
| 31 Mar 15 | 0 | -33 | 34 | 0 |
| 31 Dec 14 | 0 | -28 | 28 | 0 |
| 30 Sep 14 | 0 | -21 | 22 | 0 |
| 30 Jun 14 | 0 | -16 | 17 | 0 |
| 31 Mar 14 | 0 | -13 | 14 | 0 |
| 31 Dec 13 | 0 | -10 | 11 | 0 |
| 30 Sep 13 | 0 | -8 | 8 | 0 |
Quality Earnings: IMMU is currently unprofitable.
Growing Profit Margin: IMMU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMMU is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare IMMU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: IMMU has a negative Return on Equity (-14.42%), as it is currently unprofitable.